Paolo Manca
Overview
Explore the profile of Paolo Manca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
714
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
[The IN-HF Registry: the history and the scientific production for the Italian cardiology community]
Rizzello V, Tinti M, Gori M, Marini M, Palmieri V, De Gennaro L, et al.
G Ital Cardiol (Rome)
. 2024 Apr;
25(5):301-308.
PMID: 38639120
The Italian Network on Congestive Heart Failure (IN-CHF) project, later known as IN-HF Online, was launched in 1995 to provide the Italian cardiology community with a digital tool, standardized across...
12.
Harrold E, Keane F, Walch H, Chou J, Sinopoli J, Palladino S, et al.
Clin Cancer Res
. 2024 Mar;
30(12):2672-2683.
PMID: 38502113
Purpose: Targeted therapies have improved outcomes for patients with metastatic colorectal cancer, but their impact is limited by rapid emergence of resistance. We hypothesized that an understanding of the underlying...
13.
Germani M, Vetere G, Giordano M, Ciraci P, Capone I, Tamborini E, et al.
Front Oncol
. 2024 Feb;
13:1307545.
PMID: 38406172
Background: Retreatment with anti-EGFR monoclonal antibodies is a promising strategy in patients with wild-type (wt) metastatic colorectal cancer (mCRC) who achieved benefit from previous anti-EGFR exposure upon exclusion of mutations...
14.
Manca P, Panarello G, Sciacca S, Cipriani M
G Ital Cardiol (Rome)
. 2023 Oct;
24(11):862-864.
PMID: 37901975
No abstract available.
15.
Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner S, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37277193
Background: Subgroup analyses of randomized trials suggest the superiority of immune checkpoint inhibitor-based therapy over chemotherapy in patients with mismatch-repair deficient (dMMR) and/or microsatellite instability-high (MSI-high) advanced gastric or gastroesophageal...
16.
Manca P, Corti F, Intini R, Mazzoli G, Miceli R, Germani M, et al.
Eur J Cancer
. 2023 Apr;
187:15-24.
PMID: 37099945
Background: Immune checkpoint inhibitors (ICIs) are the standard treatment in patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). Tumour mutational burden (TMB) is a promising biomarker...
17.
Prete A, Manca P, Messina M, Formica V, Frassineti G, Zampino M, et al.
Eur J Cancer
. 2023 Feb;
182:87-97.
PMID: 36753836
Background: Molecular characteristics of squamous cell anal carcinoma (SCAC) are poorly explored. Immune checkpoint inhibitors showed limited activity in phase I/II trials, but predictive and prognostic biomarkers are lacking. Patients...
18.
Nuzzi V, Cannata A, Pellicori P, Manca P, Stolfo D, Gregorio C, et al.
Clin Res Cardiol
. 2022 Dec;
112(3):454.
PMID: 36472647
No abstract available.
19.
Pietrantonio F, Manca P, Bellomo S, Corso S, Raimondi A, Berrino E, et al.
Clin Cancer Res
. 2022 Nov;
29(3):571-580.
PMID: 36413222
Purpose: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not significantly improve survival of patients with HER2-positive metastatic gastric cancer, despite 3.3 months increase versus placebo. HER2 copy-number variation (CNV)...
20.
Delgado V, Manca P, Senni M
EuroIntervention
. 2022 Nov;
18(10):787-789.
PMID: 36412139
No abstract available.